Phase 1 Study to Determine the Immunomodulatory Activity of LY2157299 Monohydrate in Patients with Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2016
Price : $35 *
At a glance
- Drugs Galunisertib (Primary)
- Indications Solid tumours
- Focus Pharmacodynamics
- Sponsors Eli Lilly
- 04 Oct 2016 Status changed from active, no longer recruiting to completed.
- 25 Aug 2016 Planned End Date changed from 1 Jun 2018 to 1 Dec 2016.
- 25 Aug 2016 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2016.